ProCE Banner Activity

BRIGHTE: Fostemsavir Plus OBT Associated With Similar Virologic Efficacy in Most Subgroups of Heavily Treatment–Experienced Patients at Week 24

Capsule Summary
Conference Coverage

Week 24 virologic suppression rates numerically lower in patients with high baseline HIV-1 RNA levels, very low baseline CD4+ cell counts.

Released: July 30, 2018

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

Janssen

ViiV Healthcare

Partners

AIDS 2018

ProCE Banner

IAS 2018

ProCE Banner